Naimish Patel Sells 3,786 Shares of CRISPR Therapeutics (NASDAQ:CRSP) Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) insider Naimish Patel sold 3,786 shares of the firm’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $55.62, for a total value of $210,577.32. Following the completion of the sale, the insider directly owned 19,357 shares in the company, valued at approximately $1,076,636.34. The trade was a 16.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Naimish Patel also recently made the following trade(s):

• On Monday, March 16th, Naimish Patel sold 3,150 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $48.26, for a total value of $152,019.00.

CRISPR Therapeutics Price Performance

Shares of NASDAQ:CRSP traded down $1.99 on Monday, hitting $54.19. The company’s stock had a trading volume of 1,423,251 shares, compared to its average volume of 1,853,357. The company has a 50-day simple moving average of $51.36 and a 200 day simple moving average of $53.12. CRISPR Therapeutics AG has a 1 year low of $36.08 and a 1 year high of $78.48. The company has a market capitalization of $5.23 billion, a PE ratio of -8.71 and a beta of 1.74. The company has a debt-to-equity ratio of 0.32, a current ratio of 17.97 and a quick ratio of 17.96.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($1.28) earnings per share for the quarter. CRISPR Therapeutics had a negative net margin of 13,856.54% and a negative return on equity of 25.66%. The business had revenue of $1.46 million during the quarter. Sell-side analysts forecast that CRISPR Therapeutics AG will post -4.96 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CRSP has been the topic of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Monday, April 20th. Wall Street Zen upgraded CRISPR Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Truist Financial upgraded CRISPR Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Chardan Capital increased their price objective on CRISPR Therapeutics from $74.00 to $76.00 and gave the company a “buy” rating in a research report on Saturday, February 14th. Finally, Morgan Stanley reiterated an “underweight” rating and set a $33.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday, February 17th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $65.47.

Institutional Investors Weigh In On CRISPR Therapeutics

A number of large investors have recently made changes to their positions in CRSP. Mcguire Capital Advisors Inc. bought a new stake in shares of CRISPR Therapeutics in the 4th quarter worth approximately $25,000. Ramirez Asset Management Inc. bought a new stake in shares of CRISPR Therapeutics in the 4th quarter worth approximately $26,000. Rothschild Investment LLC grew its position in shares of CRISPR Therapeutics by 836.7% in the 4th quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock worth $29,000 after buying an additional 502 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. grew its position in shares of CRISPR Therapeutics by 196.9% in the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company’s stock worth $30,000 after buying an additional 382 shares during the last quarter. Finally, Optiver Holding B.V. grew its position in shares of CRISPR Therapeutics by 71.4% in the 3rd quarter. Optiver Holding B.V. now owns 504 shares of the company’s stock worth $33,000 after buying an additional 210 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.